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Dengue fever is an important tropical illness for which there is currently no virus-specific treatment. To
shed light on mechanisms involved in the cellular response to dengue virus (DV), we assessed gene
expression changes, using Affymetrix GeneChips (HG-U133A), of infected primary human cells and
identified changes common to all cells. The common response genes included a set of 23 genes significantly
induced upon DV infection of human umbilical vein endothelial cells (HUVECs), dendritic cells (DCs),
monocytes, and B cells (analysis of variance, P < 0.05). Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), one of the common response genes, was identified as a key link between type I and type
II interferon response genes. We found that DV induces TRAIL expression in immune cells and HUVECs
at the mRNA and protein levels. The induction of TRAIL expression by DV was found to be dependent on
an intact type I interferon signaling pathway. A significant increase in DV RNA accumulation was
observed in anti-TRAIL antibody-treated monocytes, B cells, and HUVECs, and, conversely, a decrease in
DV RNA was seen in recombinant TRAIL-treated monocytes. Furthermore, recombinant TRAIL inhibited
DV titers in DV-infected DCs by an apoptosis-independent mechanism. These data suggest that TRAIL
plays an important role in the antiviral response to DV infection and is a candidate for antiviral
interventions against DV.
Dengue virus (DV) has reemerged as a major global health
problem in the tropics, particularly among children (9, 26).
This mosquito-borne flavivirus, for which there is no vaccine or
antiviral treatment, causes an estimated 50 million infections
annually (32, 34). Most DV infections result in a self-limited
febrile illness (dengue fever). Less frequently, infections can
cause dengue hemorrhagic fever, a potentially fatal plasma
leakage syndrome.
DV replication can be effectively controlled after a short
period of viremia in most individuals. It is unclear, however,
what host factors induced by DV infection are involved in
regulating the virus. Increases in serum levels of type I and type
II interferons (IFNs) have been observed during DV infection
(21, 22). Pretreatment of cells with type I IFN was shown to
block DV infection of cells by a protein kinase receptor and
2-5 oligoadenylate synthase (OAS)-independent mechanism
(5), although it has been shown that DV infection inhibits type
I IFN signaling within infected cells (31).
The in vivo tropism and cellular response to DV has only
been partially understood. Macrophages (10), B cells (18, 23),
and dendritic cells (DCs) (27, 47) are known sites for DV
replication in vivo. Primary endothelial cells and hepatocytes
are infected in vitro (13, 16, 42, 46). The response to DV in
these cells may be critical to control DV replication. Previous
in vitro studies analyzed changes in gene expression induced by
DV in human umbilical vein endothelial cells (HUVECs) (46)
and monocytes (30) but reported up-regulation of different sets
of genes by DV infection. Interestingly, gene expression anal-
ysis of whole blood cells in dengue patients found that the
IFN-inducible gene response was attenuated in dengue shock
syndrome patients compared to the response in dengue hem-
orrhagic fever patients (41).
In this study, we have identified a common response pro-
file of 23 induced genes in primary human cells including
HUVECs, monocytes, DCs, and B cells infected in vitro with
DV. Signaling pathway analysis identified TRAIL (tumor
necrosis factor [TNF]-related apoptosis-inducing) as a po-
tential common linker between the IFN- and IFN- path-
ways. TRAIL is a member of the TNF family that specifically
promotes apoptosis in cancer cells by binding to and acti-
vating the death receptors DR4 and DR5 (12), resulting in
recruitment of adaptor protein FADD (Fas-associated
death domain). FADD recruits procaspase-8 into the death
receptor complex, thereby causing autoproteolytic cleavage
of procaspase-8, which in turn leads to activation of the
apoptosis signaling pathway (43). TRAIL has also been
shown to negatively regulate innate immune responses in-
dependent of apoptosis (6). Previous studies indicated that
TRAIL can function as an antiviral and antitumor protein
(2, 17, 25, 35, 37–39, 44, 45, 48) by inducing cell death.
We found that TRAIL regulates viral replication in DV-
infected monocytes at a concentration which is higher than that
used to induce cell death in tumor cell lines in vitro (1, 2).
Additionally, we show that recombinant TRAIL (rTRAIL)-
mediated inhibition of DV titers is not mediated through apop-
tosis of DV-infected DCs. These data describe an apoptosis-
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independent mechanism by which TRAIL might mediate
antiviral activity.
MATERIALS AND METHODS
Blood sample preparation and cell culture. Blood samples were obtained from
healthy U.S. volunteers at The University of Massachusetts Medical School.
Monocytes and B cells were negatively selected from heparin-anticoagulated
blood using a rosetting antibody precipitation kit (StemCell) and maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and anti-
biotics. Sample purity was determined by cell surface staining of freshly isolated
monocytes and B cells. Primary HUVECs were obtained from pooled umbilical
cords (two to five donor pools per culture). Human subject protocols were
approved by Harvard University Medical School (Institutional Review Board
#92-05383 and #85-01323). HUVECs were maintained by the Core Facility of
the Center for Excellence in Vascular Research at Harvard Medical School in
M199 medium supplemented with 10% FCS, 1 mM glutamine, endothelial cell
growth stimulant, porcine intestinal heparin, and antibiotics. HUVEC cultures
were split at a ratio of 1:3 or 1:4 for up to two passages. DV (DV type 2, strain
New Guinea C) was cultured using standard methods in the C6/36 insect cell line.
HUVECs, monocytes, and B cells were infected in vitro with DV as previously
described (46). Cells were treated with uninfected C6/36 cell supernatant as a
negative control (mock infection). Cells were collected for gene expression
analysis at 48 h postinfection (46).
CD14 microbeads (catalog number 120-000-305; Miltenyi Biotec) were used to
positively select CD14-positive cells (monocytes) from Ficoll-isolated peripheral
blood mononuclear cells from healthy donors. Monocytes were cultured for 7
days in RPMI 1640 medium supplemented with 800 U/ml of granulocyte-mac-
rophage colony-stimulating factor, 500 U/ml of interleukin-4, and 10% FCS.
Cells were stained for CD1a, CD14, HLA-DR, and CD83 on day 6 to determine
the monocyte to immature DC conversion.
Wild-type (2fTGH) and IFN- pathway mutant (U1A, U3A, U4A, and
U5A) fibroblast cells (24, 29, 33) were obtained from Paul Fisher (Columbia
University, New York, NY) and cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% FCS. The fibroblast cells were infected with
DV for 48 h.
Affymetrix GeneChip hybridization and analysis. Total cellular RNA isolated
using an RNeasy kit (Qiagen) was biotin labeled and hybridized to human
oligonucleotide microarrays (Affymetrix HG-U133A) as previously described
(46). Experiments displaying Affymetrix present call rates of 30% were in-
cluded in the analysis. Signal values from each of the 22,283 probe sets were
calculated using robust multiarray analysis (14). Signal values were transformed
using the inverse natural log. For repeated experiments, inverse natural log-
transformed robust multiarray analysis results were normalized based on the
median and geometric means and were calculated prior to importing data into
GeneSpring software (Agilent). Each GeneChip was independently normalized
to the median expression level of all genes on the chip. Each gene was then
normalized to the median expression levels of that gene. Signals with low ex-
pression levels were excluded, and expression of statistical filters was applied as
indicated. We analyzed our data by hierarchical cluster analysis using a Pearson
correlation. Reproducibility was assessed as previously described (46). For the
analysis of the common response, the following analysis was performed: expres-
sion signals for 22,283 genes were filtered to exclude those with very low signals
(2,000 genes), and the remaining genes were analyzed by one-way analysis of
variance (ANOVA) to identify genes with statistically significant differences
between DV-infected samples (five samples) and uninfected samples (five sam-
ples). Variances were calculated using the cross-gene error model, parametric
test, a P value cutoff 0.05, and the Benjamin and Hochberg false discovery rate
multiple testing correction. For hierarchical cluster analysis a Pearson correla-
tion was used.
Quantitative reverse transcription-PCR (qRT-PCR). TaqMan quantitation of
DV RNA was performed as previously described (46). TRAIL mRNA was
quantified using the same reaction conditions with TaqMan primer and probes
obtained from Applied Biosystems. Results were calculated using the standard
curve method or relative quantification method using quantitative PCR software
(Applied Biosystems).
For microfluidic card analysis or qRT-PCR, total RNA was extracted from
cells using a Qiagen RNeasy kit. RNA was subjected to 384-well microfluidic
card analysis as described by the manufacturer (Applied Biosystems). One hun-
dred nanograms of total cellular RNA was reverse transcribed using TaqMan
reverse transcription reagents in the presence of random hexamers as primers.
Reverse transcription was performed at 25°C for 10 min and 48°C for 30 min,
followed by 95°C for 5 min. For PCR, a 100-l reaction mixture through a single
port provided 2 l of total reaction mixture per sample. The 100-l PCR reaction
mixture included 5 l of cDNA, 45 l of RNase/DNase-free water, and 50 l of
TaqMan Universal PCR Master Mix (2). PCRs were cycled at 50°C for 2 min
and 94.5°C for 10 min, followed by 40 cycles of 97°C for 30 s and 59.7°C for 1 min
in the PCR signal detection system 7900 (Applied Biosystems). 	-Actin was used
as an endogenous control to equalize loading of total RNA between samples.
Each data point was measured in quadruplicate, and the standard error was
determined.
TRAIL protein detection. For TRAIL enzyme-linked immunosorbent assay
(ELISA) and TRAIL intracellular cytokine staining, TRAIL protein levels in
culture supernatants and cell lysates were measured by ELISA (R&D Systems).
The minimum detectable amount of TRAIL for this ELISA is 2.86 pg/ml. CD14
CD4
 cells (monocytes) were stained for surface TRAIL protein and CD1a
CD14
 cells (DCs) were stained for surface and intracellular TRAIL protein by
flow cytometry using monoclonal anti-TRAIL-phycoerythrin (PE) antibody (BD
Biosciences). Both monocytes and DCs were infected with DV at a multiplicity
of infection (MOI) of 0.1 for either 48 h (monocytes) or 12, 24, and 48 h (DCs).
DCs were treated with brefeldin A for the last 8 h of each time point.
TRAIL antibody treatment. Monocytes, B cells, and HUVECs were pretreated
for 24 h with TRAIL blocking monoclonal antibody (50 g/ml; R&D Systems) or
purified immunoglobulin G1 isotype control antibody followed by infection with
DV for 48 h at an MOI of 1. The antibodies were left in the culture during the
48 h DV infection.
The cells were collected by centrifugation at 500  g, washed twice in phos-
phate-buffered saline (PBS), and cell pellets were stored at 
70°C until analysis.
RNA was extracted from the cell pellet using RNeasy (Qiagen) and subjected to
TaqMan qRT-PCR for detection of TRAIL and DV RNA using 	-actin as an
endogenous control. A standard curve was run using a precalibrated DV sample
for absolute quantification of gene expression.
rTRAIL treatment. Monocytes were treated for 24 h with rTRAIL (Merck,
Germany) at concentrations from 5 to 20 g/ml and infected with DV at an
MOI of 0.1. At the end of 24 and 48 h, cells were washed with PBS (twice),
and the cell pellets were stored at 
70°C. RNA was extracted, and DV copy
number was determined using TaqMan qRT-PCR. 	-Actin was used as en-
dogenous control.
DCs were treated for 24 h with rTRAIL (Biomol, PA) and infected with DV
at an MOI of 0.1 for 12, 24, or 48 h. DCs were washed at 2 h postinfection to
remove residual virus used for infection. Cells were maintained in fresh RPMI
1640 medium containing 20 g/ml rTRAIL, 10% FCS, interleukin-4 (500 U/ml),
and granulocyte-macrophage colony-stimulating factor (800 U/ml) for 12, 24 or
48 h. At each time point, cells were stained for DV antigen (DV-fluorescein
isothiocyanate), CD1a-allophycocyanin, HLA-DR-peridinin chlorophyll protein-
Cy5.5, and CD83-PE. Plaque assay was also performed on supernatant collected
at the 48-h time point.
Detection of apoptosis in DCs. (i) Poly(ADP-ribose) polymerase 1 (PARP-1)
protein cleavage detection. Cells undergoing apoptosis cleave PARP-1 protein
(116-kDa) into two smaller fragments (85 and 25 kDa) (19). PARP-1 protein
cleavage is the last known stage in cell death to differentiate between apoptosis
and necrosis. DCs infected with DV for 48 h were washed with PBS (two washes)
and stained with PARP-1-PE antibody (BD Biosciences) followed by flow cy-
tometry analysis.
(ii) Caspase-3 and Live/Dead Aqua stain. Live/Dead Aqua stains dying cells
while active caspase-3 is an early marker for cells undergoing apoptosis (8).
DV-infected DCs either untreated or treated with TRAIL were stained for
apoptosis using caspase-3 and Live/Dead Aqua dye at 12, 24, and 48 h postin-
fection. DCs incubated in a 65°C water bath for 20 min and camptothecin B (2
mM)-treated THP-1 cells were used as positive controls for Live/Dead Aqua
stain at each time point. DCs treated with camptothecin B (2 mM/ml) for 4 h
were used as a positive control for caspase-3 stain at each time point.
Plaque assay. Culture supernatants were incubated with a monolayer of
LLCMK2 cells for 2 h. Cell monolayers were washed with PBS and overlaid with
medium viscosity (mix of high and low) carboxy methylcellulose (Sigma-Aldrich,
St. Louis, MO). Carboxy methylcellulose was removed 6 days later, and cells
were fixed and stained with 0.2% crystal violet in ethanol. DV plaques were
counted visually (36).
Statistical analysis. Means, standard deviations, and a Student’s t test were
calculated by the Excel program (Microsoft). The ANOVA was used to analyze
gene expression profiles by GeneSpring (Agilent).
Microarray data accession numbers. Microarray gene expression data are
available at GEO under accession number GSE9378.
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RESULTS
Identification of common gene expression response to DV
infection. To identify common gene expression changes in host
cells in response to DV infection, we analyzed the global gene
expression profile in HUVECs, monocytes, DCs, and B cells
using Affymetrix GeneChip arrays. Monocytes and B cells iso-
lated from healthy donor blood were80% CD14 and90%
CD19, respectively (data not shown). Monocyte-derived DCs
were 91% CD1a. The CD1a cells were stained for CD83
to confirm that the monocyte-derived DCs were immature.
FIG. 1. Gene expression analysis using HG-U133A Affymetrix GeneChips. Expression levels for the 23 DV common response genes in cells
exposed to DV. HUVECs (n 2), monocytes (n 2), and B cells (n 1) represent cells exposed in vitro to DV for 48 h. In vitro infection profiles
were normalized to C6/36 insect cell supernatant-treated samples for each cell type independently. Hierarchical cluster analysis used a Pearson
correlation. Color indicates relative changes in induction (n-fold). On the color scale, dark red represents 20-fold up-regulation, and white indicates
no change. Affymetrix microarray analysis was performed using GeneSpring software (Agilent).
TABLE 1. Biological function of the 23 DV response genes
Gene name Functional category Description GenBankaccession no.
Affymetrix
identifier
G1P2 Antiviral IFN-inducible protein (clone IF1-15K) NM_005101 205483_s_at
IRF7 Antiviral IFN regulatory factor 7 NM_004030 208436_s_at
ISG20 Antiviral IFN-stimulated gene (20 kDa) NM_002201 204698_at
OAS3 Antiviral 2–5-OAS3 (100 kDa) NM_006187 218400_at
OASL Antiviral 2–5-OAS3-like NM_003733 205660_at
RSAD2 Antiviral Radical S-adenosyl methionine domain-containing 2 AI337069 213797_at
TRIM5 Antiviral Tripartite motif-containing 5 AF220028 210705_s_at
HSXIAPAF1 Apoptosis XIAP associated factor-1 NM_017523 206133_at
TRAIL Apoptosis TNF (ligand) superfamily, member 10 U57059 202687_s_at
CD38 Cyclic ADP-ribose metabolism CD38 antigen (p45) ecto enzyme NM_001775 205692_s_at
HERC5 HECT E3 ubiquitin ligase Hect domain and RLD 5 NM_016323 219863_at
IFI44 IFN inducible IFN-induced protein 44 NM_006417 214453_s_at
IFI44L IFN inducible IFN-induced protein 44 NM_006820 204439_at
IFITM1 Immune suppression IFN-induced transmembrane protein 1 (residues 9–27) AA749101 214022_s_at
LGALS3BP Immune activation Lectin, galactoside-binding, soluble, 3 binding protein NM_005567 200923_at
USP18 Ubiquitination Ubiquitin-specific protease 18 NM_017414 219211_at
FLJ20035 Unknown RNA Hellicase/DEAD/DEXD protein Q6PK35 NM_017631 218986_s_at
FLJ38348 Unknown Coiled-coil domain-containing 75 protein CCDC75 AV755522 213294_at
HERC6 Unknown Hect domain and RLD6 NM_017912 219352_at
IFIT1 Unknown IFN-induced protein with tetratricopeptide repeat 1 NM_001548 203153_at
IFIT3 Unknown IFN-induced protein with tetratricopeptide repeat 3 NM_001549 204747_at
LY6E Unknown Lymphocyte antigen 6 complex, locus E NM_002346 202145_at
SAMD9 Unknown Sterile alpha motif domain-containing 9 NM_017654 219691_at
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Very few (1%) CD1a cells stained positive for CD83 sur-
face antigen (data not shown). All the cells tested were in-
fected with DV propagated in C6/36 mosquito cells. Control
samples were mock infected with uninfected C6/36 superna-
tants. ANOVA identified a set of 23 transcripts that demon-
strated a significant change in expression (P of 0.05) in all
cell types studied (Fig. 1 and Table 1). To confirm the gene
expression changes detected by Affymetrix GeneChip, 11
genes for which primers and probes were available were
selected for validation by qRT-PCR. qRT-PCR confirmed
up-regulation (greater than threefold) of all the 11 genes in
HUVECs (Table 2).
To identify signaling pathways associated with the host cell
response to DV infection, we analyzed our common response
gene list using Pathway Architect software (Stratagene). This
analysis found the commonly regulated genes to be predomi-
nantly regulated by IFN- and IFN- signaling pathways. In
addition, TRAIL/TNFSF10, one of the 23 common response
FIG. 2. TRAIL mRNA and protein induction in DV-infected cells. (A) TRAIL mRNA levels were measured by qRT-PCR. Monocytes were
infected with DV at an MOI of 0.1 and 1 PFU/ml, DCs were infected with DV at an MOI of 0.1 PFU/ml, and B cells were infected with DV at
an MOI of 1 PFU/ml for 48 h. TRAIL mRNA expression was quantified by qRT-PCR analysis on total RNA extracts. 	-Actin mRNA, a
constitutively expressed protein, was used as a control probe. Data shown are representative of multiple (N) experiments. (B) TRAIL protein levels
were measured in cell lysates. Monocytes (Mo) were infected with DV at an MOI of 1 PFU/cell and then cultured for 48 h. Levels of TRAIL
protein were quantified in cell lysates using a TRAIL ELISA (R&D Systems). Data shown are representative of three experiments. (C) Intra-
cellular TRAIL protein levels were determined in DCs infected with DV for 12, 24, and 48 h at an MOI of 0.1. Cells were treated with brefeldin
A for the last 8 h of each time point. Levels of TRAIL protein were quantified by flow cytometry using TRAIL-PE (BD Biosciences). Data shown
are a representation of two experiments. FITC, fluorescein isothiocyanate.
TABLE 2. qRT-PCR validation of the 11 DV response genes
Gene name
Relative increase in induction (n-fold)
determined by:a
GeneChip
analysis PCR
ISG20 15 3
LYE6E 8 4
USP18 14 5
HERC5 9 6
HSXIAPAF1 7 8
IF144 27 10
G1P2 28 15
LGALS3BP 3 15
IFI44L 58 31
IFIT1 126 32
IRF7 12 100
a qRT-PCR validation of the 11 DV response genes. In vitro DV infections
in HUVECs were analyzed by qRT-PCR using microfluidic cards. Relative
induction was calculated with qRT-PCR software (Applied Biosystems). The
results of qRT-PCR and the Affymetrix GeneChip HG-U133A were consis-
tent for HUVECs and monocytes, with 8 (70%) of the 11 genes induced
within fourfold of each other.
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genes, was identified as a potential linker of these two signaling
pathways (data not shown).
DV infection induces TRAIL/TNFSF10 mRNA and protein
production. Using real-time PCR, we tested TRAIL/TNFSF10
induction in vitro during DV infection at the mRNA level. We
found that TRAIL mRNA was induced in DV-infected mono-
cytes, B cells, and DCs (Fig. 2A). We did not detect the protein
TRAIL on the surface of DV-infected monocytes by flow cy-
tometry or in the supernatant of DV-infected monocytes by
ELISA, most likely due to the small amounts of TRAIL
present. We detected larger amounts of TRAIL protein,
180.93  101.9 pg/ml (mean  standard deviation [SD]; n 
3), in DV-infected monocyte cell lysates compared to unin-
fected monocyte lysate at 48 h after infection with DV in vitro
(Fig. 2B). These results represent the accumulation/utilization
of TRAIL inside the cell at 48 h postinfection. In DV-infected
DCs, higher intracellular TRAIL protein levels were detected
at 12 h (at 14.7%) but low levels were found at the 24- or 48-h
time points after infection, with less than 2% of the cells
expressing TRAIL (Fig. 2C). Also, the early expression of
TRAIL at the surface or intracellularly at 12 h was observed in
the uninfected DC compartment. The lack of TRAIL detec-
tion after 12 h postinfection indicates that TRAIL expression
is transient in DCs. Both monocyte and DC experiments cor-
roborate the increase in TRAIL mRNA expression originally
observed after DV infections by gene expression analysis.
TRAIL inhibits DV replication. TRAIL neutralizing anti-
bodies were used to block TRAIL function in DV-infected
monocytes, B cells, and HUVECs. The concentration of anti-
TRAIL antibody (R&D Systems) was titrated (data not
shown) to block cell surface TRAIL protein in primary mono-
cytes treated with IFN-	 (100 U/ml) as indicated by previously
published data (7). At 48 h postinfection, monocytes showed a
0.7  0.3 (mean  SD) log increase in DV RNA amount (P 
0.02, unpaired Student’s t test; n  5). In duplicate experi-
ments, an average 0.99 and 0.32 log increase in DV RNA was
observed in B cells and HUVECs, respectively (Fig. 3A). Ir-
relevant antibody treatment did not affect DV copy number in
monocytes (0.008  0.09 log increase in DV RNA).
Monocytes pretreated with 5 to 20 g/ml of rTRAIL
(Merck) showed a 0.5 to 1 log decrease in DV RNA copy
number after 24 and 48 h (Fig. 3B), respectively. We also
determined inhibition of DV infection in monocyte-derived
DCs 48 h postinfection. Since DCs are more efficiently infected
by DV than the other cells used, we were able to show by flow
cytometry the percent infected cells and to use a plaque assay
of the culture supernatant to measure progeny virus. DCs treated
with rTRAIL (20 g/ml) showed a decrease of 63.63% 23.90%
(mean  SD) in DV antigen (Fig. 4A and B). IFN- (500
U/ml), previously shown to inhibit DV in DCs (11), inhibited
DV antigen by 84.68%  17.44% (mean  SD) (Fig. 4B).
Further, DV infectious progeny was significantly reduced (P 
FIG. 3. TRAIL regulates DV replication. (A) TRAIL blocking monoclonal antibody increases DV progeny. Monocytes, B cells, HUVECs were
infected with DV at an MOI of 1 PFU/cell and then cultured for 48 h. TRAIL blocking antibody (50 ng/ml) was added 24 h prior to infection with
DV. DV copy number was quantified by qRT-PCR analysis. 	-Actin mRNA, a constitutively expressed protein, was used as a control probe. The
numbers of DV-infected cells are the means of five experiments for monocytes and two experiments each for B cells and HUVECs. Results for
nonspecific antibody-treated monocytes are the means of three experiments ( SD). (B) rTRAIL treatment inhibits DV copy number. Monocytes
were infected with DV at an MOI of 0.1 PFU/cell and then cultured for 24 and 48 h. Monocytes were pretreated with rTRAIL 6 h prior to infection
with DV. DV copy number was quantified by qRT-PCR analysis. 	-Actin mRNA, a constitutively expressed protein, was used as a control probe.
Results are the means of two experiments. Mo, monocyte.
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0.007, paired Student’s t test; n  5) in the supernatant of
DV-infected DCs treated with rTRAIL (Fig. 5). The range of
inhibition was 0.9 to 2.8 logs.
Type I IFN regulates TRAIL mRNA induction. Tyk2, STAT1,
JAK1, and IFNAR 2c mutants (U1A, U3A, U4A, and U5A)
derived from wild-type fibroblast cells (2fTGH) were used to
determine whether the IFN- signaling pathway regulates
TRAIL mRNA induction during DV infection. TaqMan qRT-
PCR was used to quantify TRAIL mRNA levels. Unlike the
wild-type cells, none of the mutant cell lines showed up-regu-
lation of TRAIL in response to DV infection (Fig. 6). These
data show that type I IFN signaling is necessary for TRAIL
mRNA induction.
TRAIL inhibition of DV is apoptosis independent. Previ-
ously published reports have found that TRAIL functions by
inducing apoptosis of cells (35). Hence, we investigated
whether rTRAIL-mediated inhibition of DV was dependent
on apoptosis of DV-infected cells. DV-infected DCs treated
with or without rTRAIL were stained for DV antigen and
Live/Dead Aqua dye or early (caspase-3) and late (PARP-1)
markers of apoptosis. The decrease in DV infection of
rTRAIL-treated DCs did not correlate with an increase in
staining with Live Dead Aqua, a dye which detects a cell in its
early stage of apoptosis (Fig. 7). Similar results for absence of
apoptosis were observed when DCs were stained for active
caspase-3 and cleaved PARP-1 proteins (data not shown).
DISCUSSION
We initially set out to identify the cellular immune responses
to DV infection. Using global gene expression profiling, we
found that IFN- and IFN- signaling pathway-inducible genes
were commonly regulated in several DV-susceptible cell types.
TRAIL, one of the common response genes, was identified as
FIG. 4. TRAIL inhibits DV antigen in monocyte-derived DCs. (A) rTRAIL treatment inhibits DV infection in DV-infected DCs. DCs were
pretreated with rTRAIL for 24 h followed by infection with DV at an MO of 0.1. At the 48-h time point the cells were stained intracellularly for
DV antigen (2H2 monoclonal antibody). Data presented from one experiment are representative of seven experiments ( SD). (B) Data from all
seven experiments are presented with SD analysis for both the rTRAIL (20 g/ml) (n  7) and IFN- (500 U/ml) (n  6) treatments. Data are
presented as percent inhibition of DV infection following rTRAIL or IFN- treatment. FITC, fluorescein isothiocyanate; APC, allophycocyanin.
FIG. 5. rTRAIL reduces levels of DV progeny in DV-infected
DCs. DCs pretreated with rTRAIL for 24 h were infected with DV for
48 h at an MOI of 0.1. At the end of the experiment culture superna-
tants were collected and stored at 
70°C. LLCMK2 cell monolayers
were exposed to the cell culture supernatants to determine the DV
titers (PFU/ml). Inhibition of DV titers was observed in rTRAIL-
treated DV-infected DC supernatants. Results for five experiments are
shown.
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a novel antiviral molecule against DV. Furthermore, our data
suggest that the rTRAIL-mediated decrease in DV infection is
mediated by a novel apoptosis-independent mechanism.
DV infection is an acute infection cleared within approxi-
mately 1 week (22). We hypothesized that there is a set of
cellular genes which is necessary to clear the virus in suscep-
tible cells. We identified a common gene expression profile of
23 differentially regulated genes from GeneChip analysis of
DV-infected HUVECs and peripheral blood mononuclear cell
subsets (B cells and monocytes). These findings extend previ-
ous studies of gene expression in DV-infected HUVECs (46)
and macrophages (30) that were limited to global gene expres-
sion analysis in one cell type. All of the 23 common response
genes were among the list of differentially expressed genes
detected in HUVECs using differential display and GeneChip
microarrays (46). These genes were not reported as up-regu-
lated by DV in the cytokine gene array study of Moreno-
Altamirano et al. (30). However, their study did not investigate
these specific genes.
Of the 23 genes that comprised the common DV response
profile, functions and/or inducers of 19 genes have been de-
scribed in the literature (Table 2). These include classical an-
tiviral response genes (OAS3 and IRF7), more recently iden-
tified antiviral genes (ISG15, HERC5, RSAD2, TRIM5,
TRAIL, OASL, and ISG20), genes regulating ubiquitination
(USP18), cell adhesion and cyclic ADP-ribose metabolism
(CD38), apoptosis (XAF1), immune suppression (IFITM1),
immune activation (LGALs3BP), and nine other genes
(FLJ20035, FLJ38348, HERC6, IFI44, IFI44L, IFIT1, IFIT3,
LY6E, and SAMD9) with unknown function. Functions of the
genes identified in this study may be pivotal in understanding
the role of the cellular responses to DV infection. Of the
common response genes, G1p2, Mx1, and OAS3 were also
associated with dengue shock in patients with severe DV in-
fection (41).
One of the common response genes, TRAIL, was identified
as a potential link between IFN- and IFN- signaling path-
ways. We selected TRAIL for further study based on its pre-
viously documented antiviral and antitumor functions (2, 17,
25, 35, 37–39, 44, 45, 48). This member of the TNF family of
ligands is capable of initiating apoptosis through the engage-
ment of its death receptors, TRAIL-R1 (DR4) and TRAIL-R2
(DR5) (4). In vitro and in vivo studies have demonstrated
tumoricidal activity of TRAIL without significant toxicity to-
ward normal cells or tissues (35, 38). TRAIL-mediated killing
by activated CD4 T cells, NK cells, and B cells has been
shown to occur with influenza virus and others (17, 37, 45).
IFNs enhance expression of TRAIL while, on the other hand,
TRAIL treatment can enhance expression of IFN-inducible
genes like IFITM1, IFIT1, STAT1, LGal3BP, and PRKR as
well as IFN-	 itself (20). The molecular cross-talk and func-
tional synergy observed between the TRAIL and IFN signaling
pathways is not limited to the genes involved in apoptosis and
may have implications for the physiologic role and mechanism
of action of TRAIL protein. Findings in this study (Fig. 3 and
6) support the idea that type I IFN, which is known to inhibit
DV, might induce TRAIL as a part of the type I IFN response
against DV.
Primary monocytes, DCs, B cells, and HUVECs infected
with DV induced TRAIL mRNA expression. TRAIL protein
levels were also found to be highly induced in DV-infected
monocyte cell lysates, but using fluorescence-activated cell
sorting, we were unable to detect TRAIL on monocyte and DC
surfaces after DV infection or secreted TRAIL protein in the
supernatant from DV-infected primary monocytes. Recently,
Matsuda et al. reported that TRAIL protein secreted by
HepG2 cells after DV infection was partly responsible for
apoptosis of uninfected HepG2 cells (28). Global gene expres-
sion analysis in DV-infected HepG2 cells and primary cells like
monocytes, B cells, and HUVECs performed in our laboratory
has shown a distinct set of differentially regulated genes in
HepG2 versus primary human cells (data not shown). Unlike
primary cells, TRAIL mRNA levels were not found to be
up-regulated in DV-infected HepG2 cells by GeneChip anal-
ysis (data not shown). DV infection of primary cells may better
reflect a physiological response. In the previous study of Mat-
suda et al., 80% of DV-infected HepG2 cells stained positive
for cell death (28), raising the possibility that the TRAIL
protein detected in the supernatant of DV-infected cells was
not secreted but resulted from cell death. DCs infected with
FIG. 6. TRAIL induction in response to DV infection is IFN- dependent. 2fTGH (wild type) and U1A, U3A, U4A, and U5A (IFN- mutant)
fibroblast cells were infected with DV at an MOI of 1 PFU/cell and then cultured for 48 h. TRAIL mRNA levels were quantified by qRT-PCR
analysis. 	-Actin mRNA, a constitutively expressed protein, was used as a control probe. Results are representative of two experiments.
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FIG. 7. Cell death flow cytometry-based assay of CD1a cells. Absence of apoptosis in rTRAIL-treated DV-infected DCs. Monocytes were pretreated
overnight with rTRAIL as described in Materials and Methods, followed by infection with DV for 48 h at an MOI of 1. Live/Dead Aqua fluorescence was used
to identify apoptotic DCs at 12 (A), 24 (B), and 48 (C) h after rTRAIL treatment and DV infection. Data from a representative experiment are shown for each
time point from a total of two (12 h and 24 h) and five (48 h) experiments. FITC, fluorescein isothiocyanate; APC, allophycocyanin.
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DV stained minimally for apoptosis detection dye (Live/Dead
Aqua) and markers (PARP-1 and caspase-3) (Fig. 7). Our
results indicate that under the conditions tested, DV infection
does not induce apoptosis in monocytes and DCs.
The concentration of rTRAIL (5 to 20 g/ml) in this study
that was able to inhibit DV replication was similar to the one
used in studies demonstrating TRAIL-induced apoptosis of
tumor cells (1, 2). Hence, we hypothesized that TRAIL might
be inhibiting DV copy number by acting as an antiviral agent
and not by inducing apoptosis. An apoptosis-independent
TRAIL antiviral function is a novel finding which should be
further studied. One possible mechanism of TRAIL antiviral
function could be TRAIL-mediated increased expression of
known or novel antiviral cellular protein(s) which are secreted
by cells.
TRAIL has been shown to mediate antiviral functions in
vivo in mouse models of influenza and encephalomyocarditis
virus infection (15). Influenza viral clearance was prolonged in
mice injected with anti-TRAIL antibody. TRAIL expressed by
NK cells was crucial to limit encephalomyocarditis virus repli-
cation in vivo (38). In this study, we observed TRAIL-depen-
dent inhibition of DV replication. Previous studies have shown
that both type I and type II IFNs are critical in controlling
different stages of DV infection in mice (40), although the
precise mechanism(s) by which IFNs mediate an antiviral re-
sponse is unknown. We postulated that TRAIL protein was
induced by and contributed to the type I IFN-mediated anti-
viral function. Using wild-type (2fTGH) and type I IFN mutant
(U1A, U3A, U4A, and U5A) fibroblast cells (24, 29, 33), we
found that induction of TRAIL gene expression by DV was
type I IFN dependent. Furthermore, TRAIL inhibited DV in a
novel apoptosis-independent manner. This is the first study to
show that TRAIL might regulate a pathogen in an apoptosis-
independent manner. Activation of the TRAIL signaling path-
way might therefore be used as an antiviral therapy in the
future.
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